To the Editor: In their study on the use of florbetapir for positron emission tomographic (PET) imaging of brain β-amyloid,1 Dr Clark and colleagues submitted to JAMA median values for PET scan reader scores but withheld critical individual reader score data that Avid Radiopharmaceuticals submitted to the Food and Drug Administration (FDA) on September 17, 2010. FDA analyses of these data show substantial interreader variability among independent, extensively trained readers of the florbetapir-PET scans for individuals in the autopsy cohort,2 emphasizing that florbetapir-PET imaging fails to provide an accurate and reliable assessment of amyloid burden.
Carome M, Wolfe S. Florbetapir-PET Imaging and Postmortem β-Amyloid Pathology. JAMA. 2011;305(18):1857-1858. doi:10.1001/jama.2011.579